Klaria Pharma
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar! Klaria's chairman interviewed on the upcoming European launch of SAF and the potential in the U.S.
CNX is aiming for SAF to reach a market share of 10-30% of the European Sumatriptan market, which is valued at approx. SEK 1 billion per year.
Klaria recently published that an external valuation by L.E.K. Consulting estimates annual global potential peak sales for SAF to be approx. USD 500 million.
Watch the entire filmed interview by clicking here.
Klaria Pharma is currently carrying out a rights issue with a subscription period from 14 October 2026 up to and including 28 October 2026. The proceeds will significantly strengthen the Company's balance sheet and thereby create room for manoeuvre, improved negotiating position vis-à-vis potential partners and thereby good conditions to maximize value for Klaria's shareholders.
More information about the rights issue can be found on the Company's website, www.klaria.com, and on the issue page www.ii.se/klaria-rights-issue-of-units-2026/